|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Image result for lac+usc logo | | | **Inpatient Treatment Guidelines for Covid-19**  **Updated: Aug 13, 2021** | | |
| These recommendations summarize current, evidence-based recommended medical management of hospitalized Covid-19 patients at LAC+USC. As new information becomes available, treatment recommendations will be updated and distributed accordingly. | | | | | |
| **Table 1: Inpatient Management by Disease Severity** | | | | | |
| **Disease Severity** | | **Recommended Therapies** | | | **Comments** |
| **Asymptomatic or minimal disease** | | Supportive Care, no specific therapies | | | SpO2 ≥ 94% on room air |
| **Supplemental O2 Requirement**  (e.g. nasal cannula, simple mask or other low flow O2 delivery device) | | Dexamethasone + remdesivir | | | Do **not** keep hospitalized to finish remdesivir course if clinically improved & stable for Safer @ Home O2 discharge. |
| **High Flow O2 Requirement**  (e.g. HFNC ≥ 30L/min) | | Dexamethasone & consider tocilizumab\* in consulation with COVID ID attending.  **Tocilizumab General Requirements**:  - Illness duration < 14 days  - AST/ALT < 1.5x ULN  - CRP >75  - GFR ≥ 30 | | | Remdesivir **NOT** recommended.  \*Tocilizumab dose is 8mg/kg x1 and requires COVID ID Attending approval, a TNF form order, and screening for latent TB and HepB. |
| **Mechanical Ventilation or ECMO** | | Dexamethasone (and consider tocilizumab in consulation with COVID ID attending). | | | Remdesivir **NOT** recommended. |
| **Table 2: Dosing and Comments on Specific Inpatient Therapeutics** | | | | | |
| **Drug** | **Dosing** | | | **Comments** | |
| Dexamethasone | 6mg IV or PO daily x10 days | | | * Demonstrated1 mortality benefit in Covid-19. * Caution or consider ID Consult if suspected, concurrent bacterial or fungal coinfection. * Equivalent glucocorticoids in drug shortage include methylprednisolone 32mg daily or prednisone 40mg daily. * Although the RECOVERY Trial participants were not continued on dexamethasone at time of discharge, average lengths of hospitalization in the study were longer than typical LAC+USC hospital stays. As such, continuation of the 10-day dexamethasone course upon discharge is recommended. | |
| **OUTPATIENT & ED/UCC** | | | | | |
| Monoclonal Antibodies  (bamlanivimab, bamlanivimab/etesavimab  and  casivirimab/imdevimab) | NOT FOR INPATIENT USE | | | * Studies of SARS-CoV-2 monoclonal antibodies have not demonstrated clinical benefit in hospitalized patients. * Limited data suggest reductions in hospitalization rates early in disease for ambulatory, high-risk patients not requiring oxygen. * Bamlanivimab-containing products are **NOT** recommended for use in California * Casivirimab/imdevimab (Regeneron) may be considered for high-risk outpatients not requiring O2. * Outpatients may be referred for consideration of monoclonal therapy by sending an email to: [MLKCOVIDMAB@dhs.lacounty.gov](mailto:MLKCOVIDMAB@dhs.lacounty.gov) * DHS ambulatory care ID physicians will review referrals and facilitate scheduling of monoclonal infusions at the MLK Ambulatory Clinic for DHS patients | |
| For patients with hypoxia and being discharged on home O2 from ED or UCC:  Dexamethasone | 6mg PO daily x10 days | | | * Only therapy to date with demonstrated1 mortality benefit in Covid-19. * Caution or consider ID Consult if suspected, concurrent bacterial or fungal coinfection. * Equivalent glucocorticoids in drug shortage include methylprednisolone 32mg daily or prednisone 40mg daily. * Although the RECOVERY Trial participants were not continued on dexamethasone at time of discharge, average length of hospitalization in the study were longer than typical LAC+USC hospital stays. As such, continuation of the 10-day dexamethasone course upon discharge is recommended. | |

**References**:

1. RECOVERY Collaborative Group, Horby P et al. Dexamethasone in Hospitalized Patients with Covid19. *N Engl J Med*. 2020 Jul 17. PMID: 32678530.
2. ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 - Final Report.

*N Engl J Med.* 2020 Nov 5;383(19):1813-1826.

1. Ackley, T et al. A Valid Warning or Clinical Lore: an Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort. *Antimicrobial Agents and Chemotherapy 65, No. 2 (2021).*
2. Goldman, JD et al for the GS-US-540-5773 Investigators. Remdesivir for 5 or 10 days in Patients with Severe Covid-19. *NEJM* 2020; 383:1827-1837.
3. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 (REMAP-CAP). *NEJM* 2021 April 22; 384(16):1491-1502.